Back to School: How biopharma can reboot drug development. Access exclusive analysis here

GeneMedicine adds element of uncertainty

Gene therapy products have entered the clinic, but the field still faces basic issues of how to deliver genes to specific tissues and how to express the genes appropriately once they have been delivered. GeneMedicine Inc. staked its claim to one delivery method when it announced last week the issuance of patents in the U.S. and Europe covering its cationic lipid technology.

GMED said it has no plans to license

Read the full 693 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE